G1 Therapeutics (GTHX) Downgraded to “Strong Sell” at BidaskClub

BidaskClub cut shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a strong sell rating in a research note released on Friday.

Several other equities analysts have also recently weighed in on GTHX. Zacks Investment Research upgraded G1 Therapeutics from a sell rating to a hold rating in a research report on Wednesday. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research report on Friday, December 21st. B. Riley began coverage on G1 Therapeutics in a research report on Thursday, February 7th. They issued a buy rating and a $55.00 price target for the company. Wedbush reiterated an outperform rating and issued a $67.00 price target on shares of G1 Therapeutics in a research report on Friday, March 1st. Finally, Raymond James began coverage on G1 Therapeutics in a research report on Wednesday, December 19th. They issued a strong-buy rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $66.00.

Shares of NASDAQ GTHX traded down $0.68 during mid-day trading on Friday, hitting $14.40. The company had a trading volume of 451,112 shares, compared to its average volume of 321,836. The stock has a market cap of $535.54 million, a PE ratio of -5.63 and a beta of 2.37. G1 Therapeutics has a 1 year low of $14.39 and a 1 year high of $69.57.

In other G1 Therapeutics news, Director Cynthia Schwalm bought 1,420 shares of G1 Therapeutics stock in a transaction that occurred on Wednesday, December 26th. The stock was acquired at an average cost of $18.45 per share, for a total transaction of $26,199.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 15.92% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc grew its position in G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after buying an additional 676 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in G1 Therapeutics by 147.7% during the fourth quarter. Meeder Asset Management Inc. now owns 4,484 shares of the company’s stock worth $87,000 after purchasing an additional 2,674 shares during the last quarter. Pacer Advisors Inc. bought a new stake in G1 Therapeutics during the third quarter worth about $111,000. Metropolitan Life Insurance Co. NY lifted its stake in G1 Therapeutics by 413.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,665 shares of the company’s stock worth $147,000 after purchasing an additional 6,172 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in G1 Therapeutics during the third quarter worth about $218,000. Institutional investors and hedge funds own 75.08% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Read More: How are the companies in the S&P 500 selected?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.